Nanoparticulate megestrol formulations

Details Nanoparticulate megestrol formulations Nanoparticulate megestrol formulations

2006-09-05

2006-09-05

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S489000, C424S491000, C424S493000, C424S494000, C424S496000, C424S497000, C424S498000, C514S169000

Reexamination Certificate

active

07101576

ABSTRACT:
The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

REFERENCES:
patent: 4783484 (1988-11-01), Violante et al.
patent: 4826689 (1989-05-01), Violanto et al.
patent: 4997454 (1991-03-01), Violante et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5298262 (1994-03-01), Na et al.
patent: 5302401 (1994-04-01), Liversidge et al.
patent: 5318767 (1994-06-01), Liversidge et al.
patent: 5326552 (1994-07-01), Na et al.
patent: 5328404 (1994-07-01), Bacon
patent: 5336507 (1994-08-01), Na et al.
patent: 5338732 (1994-08-01), Atzinger
patent: 5340564 (1994-08-01), Illig et al.
patent: 5346702 (1994-09-01), Na et al.
patent: 5349957 (1994-09-01), Yudelson
patent: 5352459 (1994-10-01), Hollister et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5401492 (1995-03-01), Kellar et al.
patent: 5429824 (1995-07-01), June
patent: 5447710 (1995-09-01), Na et al.
patent: 5451393 (1995-09-01), Liversidge et al.
patent: 5466440 (1995-11-01), Ruddy et al.
patent: 5470583 (1995-11-01), Na et al.
patent: 5472683 (1995-12-01), Illig
patent: 5494683 (1996-02-01), Liversidge et al.
patent: 5500204 (1996-03-01), Osifo
patent: 5510118 (1996-04-01), Bosch et al.
patent: 5518187 (1996-05-01), Bruno et al.
patent: 5518738 (1996-05-01), Eickhoff et al.
patent: 5521218 (1996-05-01), Osifo
patent: 5525328 (1996-06-01), Bacon et al.
patent: 5534270 (1996-07-01), De Castro
patent: 5543133 (1996-08-01), Swanson et al.
patent: 5552160 (1996-09-01), Liversidge et al.
patent: 5560931 (1996-10-01), Eickhoff et al.
patent: 5560932 (1996-10-01), Bagchi et al.
patent: 5565188 (1996-10-01), Wong et al.
patent: 5569448 (1996-10-01), Wong et al.
patent: 5571536 (1996-11-01), Eickhoff et al.
patent: 5573749 (1996-11-01), Illig
patent: 5573750 (1996-11-01), Singh
patent: 5573783 (1996-11-01), Desieno et al.
patent: 5580579 (1996-12-01), Ruddy et al.
patent: 5585108 (1996-12-01), Ruddy et al.
patent: 5587143 (1996-12-01), Wong
patent: 5591456 (1997-01-01), Franson et al.
patent: 5593657 (1997-01-01), Ruddy et al.
patent: 5605889 (1997-02-01), Curatolo et al.
patent: 5622938 (1997-04-01), Wong
patent: 5628981 (1997-05-01), Liversidge et al.
patent: 5643552 (1997-07-01), Illig
patent: 5662883 (1997-09-01), Bagchi et al.
patent: 5665331 (1997-09-01), Bagchi et al.
patent: 5718388 (1998-02-01), Czekai et al.
patent: 5718919 (1998-02-01), Ruddy et al.
patent: 5741522 (1998-04-01), Violante et al.
patent: 5747001 (1998-05-01), Wiedmann et al.
patent: 5776496 (1998-07-01), Violante et al.
patent: 5834025 (1998-11-01), De Garavilla et al.
patent: 5862999 (1999-01-01), Czekai et al.
patent: 6028065 (2000-02-01), Ragunathan
patent: 6045829 (2000-04-01), Liversidge et al.
patent: 6068858 (2000-05-01), Liversidge et al.
patent: 6153225 (2000-11-01), Lee et al.
patent: 6165506 (2000-12-01), Jain et al.
patent: 6221400 (2001-04-01), Liversidge et al.
patent: 6264922 (2001-07-01), Wood et al.
patent: 6267989 (2001-07-01), Liversidge et al.
patent: 6268356 (2001-07-01), Ragunathan
patent: 6270806 (2001-08-01), Liversidge et al.
patent: 6316029 (2001-11-01), Jain et al.
patent: 6375986 (2002-04-01), Ryde et al.
patent: 6428814 (2002-08-01), Bosch
patent: 6431478 (2002-08-01), Reed et al.
patent: 6432381 (2002-08-01), Liversidge et al.
patent: 6593318 (2003-07-01), Ragunathan
patent: 6593320 (2003-07-01), Ragunathan
patent: 6656505 (2003-12-01), Kundu et al.
patent: 2002/0012675 (2002-01-01), Jain et al.
patent: 2002/0028794 (2002-03-01), Brubaker et al.
patent: 2005/0008707 (2005-01-01), Hovey
patent: 0 338 404 (1989-04-01), None
patent: 0 371 431 (1990-06-01), None
patent: 0 577 215 (1994-01-01), None
patent: WO 96/24336 (1996-08-01), None
patent: WO 97/10814 (1997-03-01), None
patent: WO 00/72973 (2000-12-01), None
patent: WO 01/12229 (2001-02-01), None
patent: WO 01/91750 (2001-12-01), None
patent: WO 02/098565 (2002-12-01), None
BASF performance Chemicals, BASF corporation (1996).
Graham, K. K., D. J. Mikolich, et al. (1994). “Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients.” J Acquir Immune Defic Syndr 7(6):580-6.
Academy of Managed Care Pharmacy; A Format for Submission of Clinical and Economic Data in Support of Formulary consideration by Health Care Systems in the United States; Format for Formulary Submissions, Oct. 2002.
Aisner, J., H. Parnes, et al. (1990). “Appetite stimulation and weight gain with megestrol acetate.” Semin Oncol 17(6 Suppl 9):2-7.
Alakhov, V., G. Pietrzynski, et al. (2004). “Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate.” J Pharm Pharmacol 56(10):1233-41.
Alexander, et al., Medical Care at the End of life; Health Resources and Services Administration Chapter 24, pp. 493-503.
Alexander, et al., Special Populations; Health Resources and Services Administration Chapter 15, pp. 315-327.
Appendix B: Cornell Scale of Depression in Dementia, reprinted from Alexopoulos, G.S. et al., “Cornell Scale for Depression in Dementia” Biol Psychiatry Feb. 1988; 23(3):271-84.
Baraia-Etxaburu, A.J. et al., Primary adrenal failure and AIDS: report of 11 cases and review of the literature. Rev Clin Esp. Feb. 1988; 198(2):74-9.
Barini-Garcia, Magda; Resources, Health Resources and Services Administration Chapter 26, pp. 515-548.
Batterham, M. J. and R. Garsia (2001). “A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss.” Int J Androl 24(4):232-40.
Beal, et al.; Long-Term Efficacy and Safety of Dronabinol for Acquired Immunodeficiency Syndrome-Associated Anorexia; Journal of Pain and Symptom Management 1997; 14(1):7-14.
Beal, J. and N. Flynn (1995). “AIDS-associated anorexia.” J Physicians Assoc AIDS Care 2(1):19-22.
U.S. Appl. No. 11/093,149, filed Mar. 30, 2005, by Hovey.
Beehler, MD, Connie J.; U.S. Department of Health and Human Services, Chapter 6, pp. 135-155.
Beller, E., M. Tattersall, et al. (1997). “Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group.” Ann Oncol 8(3): 277-83.
Bentley, et al.; AIDS and Long-Term Care Facilities; Topics in Long-Term Care 1990; 11:202-206.
Berenstein, EG, et al.; Megestrol acetate for the treatment of anorexia-cachexia syndrome (Review); The Cochrane Library 2005, Issue 2:1-37.
Berger, et al.; Oxandrolone in AIDS-Wasting Myopathy; AIDS 1996; 10:1657-1662.
Bhasin, et al.; Effects of Testosterone Replacement with a Nongenital, Transdermal System, Androderm, in Human Immunodeficiency Virus-Infected Men with Low Testosterone Levels; Journal of Endocrinology and Metabolism 1998; 83(9):3155-3162.
Biggar, et al.; Epidemiology and Social Science; Cancer Risk in Eldery Person With HIV/AIDS; J Acquir Immune Defic Syndr 2004; 36(3):861-868.
Blaum, et al.; Factors Associated With Low Body Mass Index and Weight Loss in Nursing Home Residents; Journal of Gerontology: Medical Services 1995; 50A(3):M162-M168.
Brambilla, G. and A. Martelli (2002). “Are some progestins genotoxic liver carcinogens?” Mutat Res 512(2-3):155-63.
Breithart, MD, William; U.S. Department of Health and Human Services, Chapter 4, pp. 85-122.
Bristol-Myers Squibb; Megace, Bristol-Myers Squibb Oncology, 2002, pp. 1-5.
British Library, The; AIDS Policy & Law, 2004.
Bruera, E., K. Macmillan, et al. (1990). “A controlled trial of megastrol acetate on appetite, colaric intake, nutritional status, and other symptoms in patients with advanced cancer.” Cancer 66(6):1279-82.
Bruera, E., S. Ernst, et al. (1998). “Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.” Cancer Prev Control 2(2):74-8.
Buchanan, et al.; Analyses of Nursing Home Residents with Human Immunodeficiency Virus and

Affiliated with

Also associated with

Rating

Nanoparticulate megestrol formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nanoparticulate megestrol formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanoparticulate megestrol formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3592881